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Abstract
Objectives: To examine the trends in utilization and outcomes of tricuspid valve (TV)
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transcatheter edge‐to‐edge repair (TEER).
Background: Surgery for isolated tricuspid regurgitation is associated with high
morbidity and mortality and is rarely performed. TV TEER is an attractive alternative.
Methods: The Nationwide Readmissions Database was queried using the International Classification of Diseases, 10th Revision, procedure code for TV TEER for
years 2016–2019. The main outcomes were trends in utilization and in‐hospital
all‐cause mortality.
Results: We identified 918 hospitalizations for TV TEER. There was an uptrend in its
utilization from 13 cases in the first quarter of 2016 to 122 cases in the last quarter
of 2019 (p trend < 0.001). Concomitant mitral valve (MV) TEER was performed in
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42.1% of admissions. The overall in‐hospital mortality was 2.1%. Surgical TV
replacement was needed in 1.1% of admissions; none of them died during the
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index hospitalization. Unplanned rehospitalizations were common at 30 days
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in‐hospital mortality between isolated TV TEER and combined MV and TV TEER

(15.7%); 38.2% of those were due to heart failure. There was no difference in
(1.7% vs. 2.6%, p = 0.359). However, admissions receiving combined procedure had
lower length of stay and urgent readmission rate.
Conclusion: The current study showed that there was an increase in the utilization of
TV TEER over 2016–2019 in the United States. TV TEER was associated with low
rates of in‐hospital mortality; however, the rate of urgent readmission remains high,
mainly due to heart failure.
KEYWORDS

MitraClip, Nationwide Readmission Database, tricuspid regurgitation

Abbreviations: MR, mitral regurgitation; MV, mitral valve; TEER, transcatheter edge‐to‐edge repair; TR, tricuspid regurgitation; TV, tricuspid valve.
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| INTRODUCTION

SEDHOM

ET AL.

the ICD 10‐PCS code 02UG3JZ. Patient and hospital‐level
variables provided by HCUP NRD were used to identify demo-

Significant tricuspid regurgitation (TR) is a common valvular heart

graphics and baseline characteristics. The Elixhauser method was

disease with an estimated prevalence ranging from 0.55% to 6%1–4

used to assess comorbidities.16 The rest of the comorbidities were

5

and is associated with poor long‐term outcomes. Most cases are

identified using appropriate ICD 10‐CM codes (Table S1). The NRD

functional, secondary to tricuspid annular dilatation and/or leaflet

is a publicly available database with deidentified hospitalization

tethering in the setting of right ventricular (RV) volume or pressure

records; therefore, institutional review board approval was not

overload.5 Untreated patients develop right‐sided heart failure

required.

with peripheral edema and liver congestion.6 Medical management
involves diuretic therapy to relieve the symptoms of right‐sided
heart failure and in those with secondary TR, therapies directed

2.2 |

Outcomes

toward the primary cause can be helpful (e.g., guideline‐directed
medical therapy for heart failure or control of atrial fibrillation).5,7

The trends in utilization of TV TEER across the 4 years by quarters

Unfortunately, surgery for isolated TR is seldom performed as it is

were examined. The main outcome of interest was all‐cause in‐

associated with high morbidity and mortality (8–20%).5,8–10 The

hospital mortality. Other clinical outcomes included the rates of

benefit of the tricuspid valve (TV) surgery—either isolated or

surgical TV replacement, permanent pacemaker (PPM) implanta-

during left‐sided valve surgery—on prognosis is not clear.11

tion, cardiogenic shock, cardiac tamponade, complete atrio-

Additionally, reoperation for severe TR after left‐sided valve

ventricular (AV) block, and major bleeding events. Major bleeding

surgery is associated with high perioperative mortality reaching

was defined as intracranial hemorrhage, respiratory hemorrhage,

up to 25%.5

gastrointestinal hemorrhage, retroperitoneal hemorrhage, post-

In recent years, the interest in transcatheter therapy for severe

procedural bleeding, hemothorax, hemopericardium or the need

symptomatic TR has grown exponentially.5,7,8,12,13 Different

for blood transfusion using the appropriate ICD‐10 codes as

interventional devices and techniques are under investigation,

shown in Table S1.

including the PASCAL transcatheter valve repair system (Edwards

The outcomes in admissions receiving isolated TV TEER and in

Lifesciences)14 and the MitraClip system (Abbott Vascular).7 The

those receiving concomitant MV TEER were examined. Additionally,

off‐label transcatheter edge‐to‐edge repair (TEER) using the

the outcomes of interest were compared based on the annual

MitraClip system in the tricuspid position has been the most

hospital procedural volume and the presence or absence of PPM or

commonly used transcatheter procedure. 10,12,13 Most recently, the

implantable cardioverter‐defibrillator (ICD).

MitraClip system has been redesigned for dedicated use in TR12

The 30‐day readmission rates in the overall cohort after the

and it is currently under investigation in the TRILUMINATE trial

exclusion of those admitted in December (30‐day readmissions for

(Clinical Trial to Evaluate Cardiovascular Outcomes In Patients

hospitalizations in December could not be obtained since the NRD does

Treated With the Tricuspid Valve Repair System).15 We aimed to

not cross the calendar year) and those who died in the index admission

examine the national trends in utilization, mortality, and outcomes

were examined. The percentage of urgent heart failure readmissions

of TV TEER in recent years as reported in the Nationwide

among all urgent readmissions was identified through the ICD‐10 codes

Readmissions Database (NRD).

of the first three recorded readmission diagnoses. Finally, the 30‐day
readmission rates in admissions undergoing combined TV and MV TEER
and those undergoing isolated TV TEER were compared.

2
2.1

| MATERIALS AND METHODS
| Data source

2.3 |

Statistical analysis

The NRD, Healthcare Cost and Utilization Project (HCUP), Agency for

All analyses were conducted using the appropriate weighting,

Healthcare Research and Quality was utilized to extract the study

stratifying, and clustering samples following HCUP regula-

cohort. The NRD contains discharge data from 28 geographically

tions.17,18 Categorical variables are displayed as numbers and

dispersed States, accounting for 60% of the total US resident

percentages and compared with Pearson's χ2 or Fisher's exact tests

population and 58.2% of all US hospitalizations. The study cohort,

as appropriate. Continuous variables are summarized as medians

procedures, and outcomes were identified using the International

and interquartile range (IQR) (25th and 75th percentiles) and

Classification of Diseases, 10th Revision, Clinical Modification (ICD

compared with the Mann−Whitney U test. All p values are two‐

10‐CM) and procedure (ICD 10‐PCS) codes. The codes used are

sided with a significance threshold <0.05. Trend analysis was

summarized in Table S1.

performed using the Poisson regression method. Statistical

The NRD database was queried using the ICD 10‐PCS code for

analysis was performed using STATA Software for Windows

TV TEER (02UJ3JZ) for the years 2016–2019. Those who under-

(version 17.0; StataCorp LLC) and IBM SPSS Statistics for

went concomitant mitral valve (MV) TEER were identified using

Windows (version 27.0; IBM Corp).

SEDHOM
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| RESULTS

3.1 | Characteristics and outcomes of admissions
undergoing TV TEER

3

3.2 | Characteristics and outcomes of admissions
undergoing combined TV and MV TEER
Combined TV and MV TEER was performed in 387 (42.1%)
admissions. The baseline demographics, comorbidities, and hospital

A total of 918 weighted hospitalizations undergoing TV TEER were

characteristics are shown in Table 1. Admissions undergoing the

identified during the study period. There was an uptrend in the

combined procedure were older (81 [IQR: 73–86] vs. 76 [IQR: 68–83]

utilization from 13 cases in the first quarter of 2016 to 122 cases in

years, p < 0.001) and had higher prevalence of pulmonary hyper-

the last quarter of 2019 (p trend < 0.001) (Figure 1). The median

tension (45% vs. 34.5%, p = 0.002). History of the prosthetic valve

hospital annual procedural volume was 9 (IQR: 4–23) procedures/

was less common compared with admissions undergoing isolated TV

year. The baseline demographics, comorbidities, and hospital char-

TEER (7.2% vs. 19.8%, p < 0.001).

acteristics are shown in Table 1 and the outcomes and complications

Compared with those undergoing isolated TV TEER, admissions

are shown in Table 2. The median age was 78 (IQR: 70–85) years and

undergoing combined TV and MV TEER had similar rates of all‐cause

57.7% of patients were females. Congestive heart failure (91%),

in‐hospital mortality (2.6% vs. 1.7%, p = 0.36), cardiac tamponade

systemic hypertension (83.8%), and atrial fibrillation (80%) were the

(0.3% vs. 1.3%, p = 0.15), and cardiogenic shock (5.7% vs. 9.2%,

most common comorbidities. Most of the procedures were per-

p = 0.06) (Table 2). Bleeding complications were similar between both

formed in teaching (93.2%) or large hospitals (84.9%).

groups. However, complete AV block (1.3% vs. 3.8%, p = 0.02), PPM

The overall all‐cause in‐hospital mortality was 2.1%. Surgical TV

implantation (0.3% vs. 2.8%, p = 0.003), and surgical TV replacement

replacement was needed in 1.1% of hospitalizations; none of them

(0% vs. 1.9%, p = 0.007) were less common in the combined

died during the index hospitalization. Cardiogenic shock occurred in

procedure. Additionally, the LOS was shorter, and the rate of urgent

7.7%, tamponade in 0.9%, and complete AV block in 2.7% of

readmissions was lower in admissions undergoing the combined

admissions. PPM implantation was performed in 1.7% admissions.

procedure.

The overall bleeding complications were low and none of the
admissions had intracranial hemorrhage. The median length of stay
(LOS) was 4 days (IQR: 1–9). The urgent 30‐day readmission rate was

4 |
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15.7%; 38.2% of these were due to heart failure. Hospitals with a
high procedural volume (≥23 procedures/year, i.e., 75th percentile)

In this analysis of the trends and outcomes of TV TEER using the

were associated with a trend toward lower all‐cause in‐hospital

NRD for years 2016–2019, we found that: (1) The number of

mortality without reaching statistical significance (0.5% vs. 2.6%,

admissions undergoing TV TEER increased over the study period,

p = 0.06). Additionally, none of the admissions in high‐volume

from 13 in the first quarter of 2016 to 122 in the last quarter of

hospitals required surgical TV replacement (Table 3).

2019. (2) The overall rate of all‐cause in‐hospital mortality in

In patients with a history of PPM or ICD implantation (19.8%,

admissions undergoing TV TEER was 2.1%. TV surgery was needed

n = 182), all‐cause in‐hospital mortality (3.8% vs. 1.6%, p = 0.077),

in 1.1% of admissions; none of them died during the index

need for surgical TV replacement (2.2% vs. 0.8% p = 0.116), and

hospitalization. (3) 42.1% of admissions underwent concomitant

bleeding complications were similar to those patients without such

MV TEER and were associated with a similar rate of all‐cause in‐

history as shown in Table S2.

hospital mortality and bleeding complications. (4) The urgent 30‐day

F I G U R E 1 National trends in transcatheter
edge‐to‐edge repair of the tricuspid valve. TEER,
transcatheter edge‐to‐edge repair, TV, tricuspid
valve [Color figure can be viewed at
wileyonlinelibrary.com]
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Baseline patients' and hospitals' characteristics of admissions undergoing TV TEER
Combined TV
and MV
TEER (n = 387)

Overall
(n = 918)

Isolated TV
TEER
(n = 531)

Age, median (IQR), mean ± SD

78 (70–85),
75.4 (12.4)

76 (68–83),
73.6 (13.3)

Female, n (%)

530 (57.7)

324 (61)

206 (53.2)

0.021

Heart failure, n (%)

836 (91)

482 (90.8)

354 (91.2)

0.907

Hypertension, n (%)

770 (83.8)

440 (82.9)

330 (85.1)

0.415

Atrial fibrillation/flutter, n (%)

734 (80)

416 (78.3)

318 (82.2)

0.157

History of smoking, n (%)

266 (29)

159 (29.9)

107 (27.6)

0.462

Anemia, n (%)

280 (30.5)

172 (32.4)

108 (27.9)

0.147

Diabetes mellitus, n (%)

234 (25.5)

155 (29.2)

79 (20.4)

0.003

Chronic pulmonary disease, n (%)

206 (22.4)

118 (22.2)

88 (22.7)

0.873

Pulmonary hypertension, n (%)

357 (38.9)

183 (34.5)

Prior CABG, n (%)

171 (18.6)

98 (18.4)

73 (18.9)

0.864

Coagulopathy, n (%)

168 (18.3)

104 (19.5)

64 (16.5)

0.262

History of permanent pacemaker
or ICD, n (%)

182 (19.8)

109 (20.5)

73 (18.9)

0.558

Prior stroke, n (%)

95 (10.3)

56 (10.5)

39 (10.1)

0.913

Prior MI, n (%)

98 (10.7)

50 (9.4)

48 (12.4)

0.160

155 (16.9)

103 (19.4)

52 (13.4)

0.020

81 (73–86), 77.9 (10.5)

p value
<0.001

Comorbidities

Severe renal disease, n (%)

174 (45)

0.002

Morbid obesity, n (%)

46 (5)

30 (5.6)

16 (4.1)

0.359

Sever liver disease, n (%)

31 (3.4)

22 (4.1)

9 (2.3)

0.143

Prior PCI, n (%)

17 (1.8)

9 (1.7)

8 (2.1)

0.805

0 (0)

0 (0)

16 (1.7)

7 (1.3)

9 (2.3)

0.309

133 (14.5)

105 (19.8)

28 (7.2)

<0.001

Large‐sized hospital, n (%)

781 (84.9)

469 (88.2)

312 (80.4)

0.001

Teaching hospital, n (%)

856 (93.2)

515 (97)

341 (88.1)

<0.001

Medicare, n (%)

779 (84.9)

451 (84.9)

328 (84.8)

Carcinoid syndrome, n (%)
Carotid disease, n (%)

0 (0)

Infective endocarditis, n (%)
History of valve prothesis, n (%)
Hospital and payer

1

Abbreviations: CABG, coronary artery bypass surgery; ICD, implantable cardioverter‐defibrillator; IQR, interquartile range; MI, myocardial infarction; MV,
mitral valve; PCI, percutaneous coronary intervention; TEER, transcatheter edge‐to‐edge repair; TV, tricuspid valve.

readmission rate was 15.7%; 38.2% of these were due to heart

steering the MitraClip system for mitral regurgitation (MR) especially in

failure.

patients with complex or unusual anatomy.7 However, the urgent 30‐day

The utilization of TV TEER in the United States showed impressive

readmission rates were high reflecting the magnitude of comorbidities

growth over the study years, and it was associated with low in‐hospital

especially heart failure and may point to the fact that the majority of

mortality and complications. Data from previous studies showed an in‐

these patients receive such therapy at an advanced stage of their disease.

hospital mortality rate ranging from 2.5% to 5%.7,10 In the current real‐

Although the optimal timing of TV intervention remains controversial, an

world more recent analysis, we found even lower in‐hospital mortality of

early approach, before significant RV dilation and systolic dysfunction

2.1% which can be partially explained by the amount of experience in

occur, should be further studied.

SEDHOM
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TABLE 2

5

Outcomes of TV TEER
Overall (n = 918)

In‐hospital mortality, n (%)
Discharge to a facility, n (%)
Urgent readmission, n (%)

a

Isolated TV TEER (n = 531)

Combined TV and MV
TEER (n = 387)

p value

19 (2.1)

9 (1.7)

10 (2.6)

0.359

122 (13.3)

77 (14.5)

45 (11.6)

0.238

128/817 (15.7)

90/475 (18.9)

38/342 (11.1)

0.002

Cardiac complications
Need for surgical TV replacement, n (%)

10 (1.1)

10 (1.9)

0 (0)

0.007

Need for PPM implantation, n (%)

16 (1.7)

15 (2.8)

1 (0.3)

0.003

Complete AV block, n (%)

25 (2.7)

20 (3.8)

5 (1.3)

0.024

Cardiogenic shock, n (%)

71 (7.7)

49 (9.2)

22 (5.7)

0.060

8 (0.9)

7 (1.3)

1 (0.3)

0.148

Ischemic stroke, n (%)

6 (0.7)

4 (0.8)

2 (0.5)

1

Hemorrhagic stroke, n (%)

0 (0)

0 (0)

0 (0)

Intracranial hemorrhage, n (%)

0 (0)

0 (0)

0 (0)

Postprocedural bleeding, n (%)

15 (1.6)

11 (2.1)

4 (1)

0.295

Respiratory hemorrhage, n (%)

20 (2.2)

12 (2.3)

8 (2.1)

1

Gastrointestinal bleeding, n (%)

25 (2.7)

14 (2.6)

11 (2.8)

0.841

Retroperitoneal bleeding, n (%)

3 (0.3)

3 (0.6)

0 (0)

0.268

Hemothorax, n (%)

2 (0.2)

2 (0.4)

0 (0)

0.512

Hemopericardium, n (%)

0 (0)

0 (0)

0 (0)

69 (7.5)

46 (8.6)

23 (5.9)

3 (0.3)

2 (0.4)

1 (0.3)

1

10 (1.1)

7 (1.3)

3 (0.8)

0.532

0 (0)

0 (0)

0 (0)

Vasopressors, n (%)

17 (1.8)

10 (1.9)

Mechanical ventilation, n (%)

54 (5.5)

32 (6)

Tamponade, n (%)
Neurological complications

Bleeding complications

Blood transfuison, n (%)

0.130

Circulatory and ventilatory support
Impella, n (%)
Intra‐aortic balloon pump, n (%)
ECMO, n (%)

LOS (median, IQR) (days)
Cost (median, IQR) (US dollars)

4 (1–9)
50,736 (36,464−77,285)

5 (2–10)
46,518 (35,053–68,259)

7 (1.8)
19 (4.9)
3 (1–7)
58,049 (40,026–81,242)

1
0.560
<0.001
<0.001

Abbreviations: AV, atrioventricular; ECMO, extracorporeal membrane oxygenation; IQR, interquartile range; LOS, length of stay; MV, mitral valve; PPM,
permanent pacemaker; TEER, transcatheter edge‐to‐edge repair; TV, tricuspid valve.
a

After the exclusion of those admitted in December and those who died in the index admission.

As with most interventional procedures, the learning curve and

The presence of a pacemaker or ICD lead can be challenging but

operator experience play an important role in procedural success and

it is not an absolute contraindication for TV TEER.6 One‐third of the

clinical outcomes. The current analysis showed that annual proce-

patients from large registries7,10 had PPM or ICD lead. In the current

dural volume ≥ 23 procedures/year was associated with a trend

analysis, ~20% of admissions had a history of ICD or PPM, and they

toward lower mortality. Additionally, none of the admissions in high‐

were associated with similar in‐hospital mortality and other compli-

volume hospitals required surgical TV replacement. In the TriValve

cations compared with those without such history. Careful patient

(Transcatheter Tricuspid Valve Therapies) registry, the procedural

selection using transthoracic and transesophageal echocardiography

success in the first two patients treated at each site was 46.4%

is needed for determining patients' eligibility for the procedure.6 The

compared with 81% in the subsequent patients.

10

utilization of intracardiac echocardiogram offers an alternative

6
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Outcomes of TV TEER based on hospital volumes
Hospitals performing ≥ 23
procedures/year (n = 220)

In‐hospital mortality, n (%)

Hospitals performing < 23
procedures/year (n = 698)

p value

1 (0.5)

18 (2.6)

0.058

Need for surgical TV replacement,
n (%)

0 (0)

10 (1.4)

0.129

Need for PPM implantation, n (%)

2 (0.9)

15 (2.1)

0.388

Complete AV block, n (%)

2 (0.9)

22 (3.2)

0.088

Cardiogenic shock, n (%)

17 (7.7)

53 (7.6)

1

0 (0)

8 (1.1)

0.210

0 (0)

5 (0.7)

0.345

Cardiac complications

Tamponade, n (%)
Neurological complications
Ischemic stroke, n (%)
Bleeding complications
Postprocedural bleeding, n (%)

2 (0.9)

13 (1.9)

0.542

Respiratory hemorrhage, n (%)

6 (2.7)

14 (2)

0.596

Retroperitoneal bleeding, n (%)

0 (0)

Gastrointestinal bleeding, n (%)

8 (3.6)

Hemothorax, n (%)

0 (0)

2 (0.3)

Blood transfuison, n (%)

17 (7.7)

52 (7.4)

Impella, n (%)

0 (0)

3 (0.4)

Intra‐aortic balloon pump, n (%)

0 (0)

10 (1.4)

0.129

Vasopressors, n (%)

0 (0)

17 (2.4)

0.018

13 (5.9)

38 (5.5)

0.866

3 (0.4)
17 (2.4)

1
0.346
1
0.884

Circulatory and ventilatory support

Mechanical ventilation, n (%)
LOS (median, IQR) (days)
Cost (median, IQR) (US dollars)

4 (2–9)

4 (1–9)

50,597 (38,057–66,417)

50,944 (36,022–79,911)

1

0.624
0.519

Abbreviations: AV, atrioventricular; ECMO, extracorporeal membrane oxygenation; IQR, interquartile range; LOS, length of stay; MV, mitral valve; PPM,
permanent pacemaker; TEER, transcatheter edge‐to‐edge repair; TV, tricuspid valve.

imaging technique to help leaflet grasping, but this is still an emerging
19,20

technique.

Current data suggest that TV TEER is a safe procedure.7,10,21–23
Combining the safety data from the two largest studies to date7,10

higher complications rates did not result in higher in‐hospital
mortality, significant comorbidities would worsen the quality of life
of these patients who might be already suffering in the terminal stage
of their disease.

compromising 313 patients, conversion to open‐heart surgery was

One of the advantages of the TV TEER is the ability to treat

needed only in 1 patient (0.3%), stroke occurred in 2 patients (0.6%),

concomitant MR during the same procedure using the same vascular

bleeding in 18 patients (5.7%), pericardial effusion or tamponade in

access.12 It is estimated that about 20% of patients undergoing MV

1 patient (0.3%). However, in our analysis, the rates of adverse

TEER have also significant TR12 and that in two‐thirds of the cases it

outcomes were somewhat higher. Notably, surgical TV replacement

persists even after improvement in MR.24 Residual significant TR

was needed in six (1.1%) cases, cardiac tamponade occurred in 0.9%

after MV TEER is associated with worse outcomes.6 Despite possible

and complete AV block occurred in 2.7% of admissions. Higher

improvement in the degree of functional TR following MV TEER,25,26

adverse outcomes in our analysis can be partially explained by the

the long‐term durability of this improvement is unclear.8 In the

burden of comorbidities in our study population especially heart

current analysis, ~42% of admissions underwent concomitant MV

failure (91%), atrial fibrillation (80%), and pulmonary hypertension

TEER which is similar to what is reported in previous studies.7,10 We

(~39%). As stated earlier, the optimal timing of TV TEER and operator

found that admissions undergoing both procedures were not

experience plays an important role in clinical outcomes. Although

associated with increased risk of in‐hospital mortality or worse

SEDHOM
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outcomes. In fact, those patients had lower LOS, lower urgent
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readmission rates, and less need for TV replacement or PPM
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